Intratumoral Injection Therapy Market is expected to reach USD 630.39 million by 2031

Intratumoral Injection Therapy Market Trends & Forecast

According to a research study published by Knowledge Sourcing Intelligence (KSI), the intratumoral injection therapy market will expand from USD 418.98 million in 2026 to USD 630.39 million in 2031 at a CAGR of 3.8% during the forecast period.

Intratumoral Injection Therapy Market involves the direct delivery of therapeutic agents into a tumor mass to maximize local treatment effects while reducing systemic exposure. This approach is increasingly being explored for a wide range of malignancies, including melanoma, head and neck cancer, breast cancer, liver cancer, lung cancer, and other solid tumors. Therapeutic modalities administered through intratumoral injection include oncolytic viruses, immune checkpoint modulators, cytokines, toll-like receptor agonists, cell therapies, and gene therapies.

The growing understanding of the tumor microenvironment has accelerated research into therapies capable of stimulating localized and systemic anti-tumor immune responses. Pharmaceutical and biotechnology companies are investing heavily in intratumoral immunotherapy programs aimed at improving patient outcomes and overcoming resistance associated with conventional therapies.

Request a free sample copy or view the report summary: Intratumoral Injection Therapy Market Report

Intratumoral Injection Therapy Market Report Highlights

• Rising clinical adoption of localized immunotherapy approaches is driving demand for intratumoral injection therapies across multiple solid tumor indications.

• Advances in oncolytic virus development, gene therapies, and immune-modulating agents are expanding the therapeutic potential of intratumoral treatment strategies.

• Increasing utilization of image-guided administration technologies is improving treatment precision and patient outcomes.

• Growing investments in combination therapies involving checkpoint inhibitors and intratumoral agents are supporting robust pipeline growth.

Intratumoral Injection Therapy Market Growth Drivers and Restraints

Growth Drivers:

• The need for treatments that maximize anti-tumor activity while minimizing systemic adverse effects is driving the adoption of intratumoral injection approaches. Direct tumor administration enables higher local drug concentrations and enhanced immune activation.

• Expanding research into tumor microenvironment modulation, oncolytic virotherapy, cytokine therapies, and gene-based treatments is supporting the development of innovative intratumoral therapeutic candidates.

Restraints:

• Deep-seated tumors, specialized administration requirements, and variability in treatment response may restrict widespread adoption. Additionally, regulatory challenges and lengthy clinical development timelines can impact market growth.

Intratumoral Injection Therapy Market Growth Key Development

• March 2026: NANOBIOTIX announced the presentation of First Data from a Randomized Phase 2 Clinical Trial Evaluating JNJ-1900 (NBTXR3) in Stage 3 Inoperable Lung Cancer.

• May 2026 – Replimune Group, Inc., a clinical-stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today presented 3-year landmark overall survival data from the IGNYTE clinical trial of RP1 plus nivolumab in patients with anti-PD-1-failed melanoma during an oral session at the 2026 American Society of Clinical Oncology annual meeting.

• Feb 2025- Oncolytics Biotech® Strengthens Its Pipeline in 2025 with Key Pancreatic and Anal Cancer Advances in Addition to Metastatic Breast Cancer

Intratumoral Injection Therapy Market Growth Segmentation

Knowledge Sourcing Intelligence has segmented the Intratumoral Injection Therapy Market Growth based on therapy type, indication, line of therapy, end-user, and region:

Intratumoral Injection Therapy Market Growth, By Therapy Type

• Oncolytic Viruses

• Cytokine-Based Therapies

• Gene Therapy Approaches

• Immunomodulators

Intratumoral Injection Therapy Market Growth By Indication

• Melanoma

• Head and Neck Cancer

• Breast Cancer

• Liver Cancer

• Other Solid Tumors

Intratumoral Injection Therapy Market Growth, By Line of Therapy

• First-Line

• Second-Line

• Third Line and Beyond

Intratumoral Injection Therapy Market Growth, By End-User

• Hospitals

• Cancer Speciality Clinics

• Ambulatory Care Centers

Intratumoral Injection Therapy Market Growth By Region

• North America

  • USA

  • Canada

  • Mexico

• Europe

  • United Kingdom

  • Germany

  • France

  • Italy

  • Spain

  • Others

• Asia Pacific

  • China

  • India

  • Japan

  • South Korea

  • Australia

  • Thailand

  • Others

• South America

  • Brazil

  • Argentina

  • Others

• Middle East and Africa (MEA)

  • Saudi Arabia

  • UAE

  • Others

Intratumoral Injection Therapy Market Growth Key Players

• Amgen Inc

• Daiichi Sanovo Company, Limited

• Nanobiotix

• Replimune Group, Inc.

• Oncolytics Biotech Inc.

• Genelux Corporation

• Philogen S.p.A.

• Istari Oncology

• DNatrix, Inc

• Regeneron Pharmaceuticals, Inc.